Characterization of full-length CNBP expanded alleles in myotonic dystrophy type 2 patients by Cas9-mediated enrichment and nanopore sequencing

Abstract

Myotonic dystrophy type 2 (DM2) is caused by CCTG repeat expansions in the CNBP gene, comprising 75 to >11,000 units and featuring extensive mosaicism, making it challenging to sequence fully-expanded alleles. To overcome these limitations, we used PCR-free Cas9-mediated nanopore sequencing to characterize CNBP repeat expansions at the single-nucleotide level in nine DM2 patients. The length of normal and expanded alleles can be assessed precisely using this strategy, agreeing with traditional methods, and revealing the degree of mosaicism. We also sequenced an entire ~50 kbp expansion, which has not been achieved previously for DM2 or any other repeat-expansion disorders. Our approach precisely counted the repeats and identified the repeat pattern for both short interrupted and uninterrupted alleles. Interestingly, in the expanded alleles, only two DM2 samples featured the expected pure CCTG repeat pattern, while the other seven presented also TCTG blocks at the 3′ end, which have not been reported before in DM2 patients, but confirmed hereby with orthogonal methods. The demonstrated approach simultaneously determines repeat length, structure/motif and the extent of somatic mosaicism, promising to improve the molecular diagnosis of DM2 and achieve more accurate genotype-phenotype correlations for the better stratification of DM2 patients in clinical trials.

Data availability

The sequencing data generated in this study have been submitted to the NCBI BioProject database (https://www.ncbi.nlm.nih.gov/bioproject/) under accession number PRJNA818354. For revision purposes, reviewers can download data from the following link: https://dataview.ncbi.nlm.nih.gov/object/PRJNA818354?reviewer=1g4lp9ijkgv5s07is6imnot6ch

The following data sets were generated

Article and author information

Author details

  1. Massimiliano Alfano

    Department of Biotechnology, University of Verona, Verona, Italy
    Competing interests
    No competing interests declared.
  2. Luca De Antoni

    Department of Biotechnology, University of Verona, Verona, Italy
    Competing interests
    No competing interests declared.
  3. Federica Centofanti

    Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
    Competing interests
    No competing interests declared.
  4. Virginia Veronica Visconti

    Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
    Competing interests
    No competing interests declared.
  5. Simone Maestri

    Department of Biotechnology, University of Verona, Verona, Italy
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1192-0684
  6. Chiara Degli Esposti

    Department of Biotechnology, University of Verona, Verona, Italy
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5974-4915
  7. Roberto Massa

    Department of Systems Medicine (Neurology), University of Rome Tor Vergata, Rome, Italy
    Competing interests
    No competing interests declared.
  8. Maria Rosaria D'Apice

    Laboratory of Medical Genetics, University of Rome Tor Vergata, Rome, Italy
    Competing interests
    No competing interests declared.
  9. Giuseppe Novelli

    Laboratory of Medical Genetics, University of Rome Tor Vergata, Rome, Italy
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7781-602X
  10. Massimo Delledonne

    Department of Biotechnology, University of Verona, Verona, Italy
    Competing interests
    Massimo Delledonne, is a partner of Genartis srl.
  11. Annalisa Botta

    Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
    For correspondence
    botta@med.uniroma2.it
    Competing interests
    No competing interests declared.
  12. Marzia Rossato

    Department of Biotechnology, University of Verona, Verona, Italy
    For correspondence
    marzia.rossato@univr.it
    Competing interests
    Marzia Rossato, is a partner of Genartis srl, Verona.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6101-1550

Funding

Muscular Dystrophy Association (MDA 876149)

  • Massimo Delledonne

Italian DiMio onlus association (DM0000010)

  • Annalisa Botta

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: The study was approved by the institutional review board of Policlinico Tor Vergata (document no. 232/19). All experimental procedures were carried out according to The Code of Ethics of the World Medical Association (Declaration of Helsinki). Informed consent was obtained from all nine participants and all samples and clinical information were anonymized immediately after collection using a unique alphanumeric identification code.

Copyright

© 2022, Alfano et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,654
    views
  • 320
    downloads
  • 11
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Massimiliano Alfano
  2. Luca De Antoni
  3. Federica Centofanti
  4. Virginia Veronica Visconti
  5. Simone Maestri
  6. Chiara Degli Esposti
  7. Roberto Massa
  8. Maria Rosaria D'Apice
  9. Giuseppe Novelli
  10. Massimo Delledonne
  11. Annalisa Botta
  12. Marzia Rossato
(2022)
Characterization of full-length CNBP expanded alleles in myotonic dystrophy type 2 patients by Cas9-mediated enrichment and nanopore sequencing
eLife 11:e80229.
https://doi.org/10.7554/eLife.80229

Share this article

https://doi.org/10.7554/eLife.80229

Further reading

    1. Genetics and Genomics
    2. Microbiology and Infectious Disease
    Jessica Gray, Von Vergel L Torres ... Ian R Henderson
    Research Article

    Klebsiella pneumoniae is a global public health concern due to the rising myriad of hypervirulent and multidrug-resistant clones both alarmingly associated with high mortality. The molecular mechanisms underpinning these recalcitrant K. pneumoniae infection, and how virulence is coupled with the emergence of lineages resistant to nearly all present-day clinically important antimicrobials, are unclear. In this study, we performed a genome-wide screen in K. pneumoniae ECL8, a member of the endemic K2-ST375 pathotype most often reported in Asia, to define genes essential for growth in a nutrient-rich laboratory medium (Luria-Bertani [LB] medium), human urine, and serum. Through transposon directed insertion-site sequencing (TraDIS), a total of 427 genes were identified as essential for growth on LB agar, whereas transposon insertions in 11 and 144 genes decreased fitness for growth in either urine or serum, respectively. These studies not only provide further knowledge on the genetics of this pathogen but also provide a strong impetus for discovering new antimicrobial targets to improve current therapeutic options for K. pneumoniae infections.

    1. Developmental Biology
    2. Genetics and Genomics
    Nathan D Harry, Christina Zakas
    Research Article

    New developmental programs can evolve through adaptive changes to gene expression. The annelid Streblospio benedicti has a developmental dimorphism, which provides a unique intraspecific framework for understanding the earliest genetic changes that take place during developmental divergence. Using comparative RNAseq through ontogeny, we find that only a small proportion of genes are differentially expressed at any time, despite major differences in larval development and life history. These genes shift expression profiles across morphs by either turning off any expression in one morph or changing the timing or amount of gene expression. We directly connect the contributions of these mechanisms to differences in developmental processes. We examine F1 offspring – using reciprocal crosses – to determine maternal mRNA inheritance and the regulatory architecture of gene expression. These results highlight the importance of both novel gene expression and heterochronic shifts in developmental evolution, as well as the trans-acting regulatory factors in initiating divergence.